– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – –.
Guggenheim reiterated their buy rating on shares of Cabaletta Bio (NASDAQ:CABA – Free Report) in a research note released on Monday morning, Benzinga reports. Guggenheim currently has a $34.00 price objective on the stock. Separately, HC Wainwright raised their price target on Cabaletta Bio from $15.00 to $17.00 and gave the company a buy rating […]
Cabaletta Bio, Inc (NASDAQ:CABA) Receives Average Recommendation of Buy from Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Guggenheim reaffirmed their buy rating on shares of Cabaletta Bio (NASDAQ:CABA – Free Report) in a research report released on Monday, Benzinga reports. They currently have a $34.00 target price on the stock. Separately, HC Wainwright upped their target price on shares of Cabaletta Bio from $15.00 to $17.00 and gave the company a buy […]
Cabaletta Bio (NASDAQ:CABA – Get Free Report) had its price target hoisted by HC Wainwright from $15.00 to $17.00 in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 24.82% from […]